Antitumor evaluation and molecular docking study of substituted 2-benzylidenebutane-1,3-dione, 2-hydrazonobutane-1,3-dione and trifluoromethyl-1H-pyrazole analogues

References

• Myers CE, Chabner BA. Anthracyclines. In: Chabner BA, Collins JM, eds. Cancer chemotherapy: principles and practice. Philadelphia (PA): Lippincott; 1990:314–28
   Google Scholar
• Varmus H. The new era in cancer research. Science 2006;312:1162–5
   PubMed Web of Science ®Google Scholar
• Tsai JY, Lee MJ, Chang MD, et al. Effects of novel human cathepsin S inhibitors on cell migration in human cancer cells. J Enzyme Inhib Med Chem 2014;29:538–46
   PubMed Web of Science ®Google Scholar
• Kucukoglu K, Gul HI, Cetin-Atalay R, et al. Synthesis of new N,N′-bis[1-aryl-3-(piperidine-1-yl)propylidene]hydrazine dihydrochlorides and evaluation of their cytotoxicity against human hepatoma and breast cancer cells. J Enzyme Inhib Med Chem 2014;29:420–6
   PubMed Web of Science ®Google Scholar
• Sharma A, Tiwari M, Supuran CT. Novel coumarins and benzocoumarins acting as isoform-selective inhibitors against the tumor-associated carbonic anhydrase IX. J Enzyme Inhib Med Chem 2014;29:292–6
   PubMed Web of Science ®Google Scholar
• Eckhardt S. Recent progress in the development of anticancer agents. Curr Med Chem 2002;2:419–39
   Google Scholar
• Fricker J. Tyrosine kinase inhibitors: the next generation. Lancet Oncol 2006;7:621
   PubMed Web of Science ®Google Scholar
• Sadek MM, Serrya RA, Kafafy AH, et al. Discovery of new HER2/EGFR dual kinase inhibitors based on the anilinoquinazoline scaffold as potential anti-cancer agents. J Enzyme Inhib Med Chem 2014;29:215–22
   PubMed Web of Science ®Google Scholar
• Srinivasan M, Trivadi SG. Tyrosine kinase inhibitors in cancer therapy. Clin Biochem 2004;37:618–35
   PubMed Web of Science ®Google Scholar
• Bridges AJ. The rationale and strategy used to develop a series of highly potent, irreversible, inhibitors of the epidermal growth factor receptor family of tyrosine kinases. Curr Med Chem 1999;6:825–43
   PubMed Web of Science ®Google Scholar
• Barlesi F, Tchouhadjian C, Doddoli C, et al. Gefitinib (ZD1839, Iressa) in non-small-cell lung cancer: a review of clinical trials from a daily practice perspective. Fundam Clin Pharmacol 2005;19:385–93
   PubMed Web of Science ®Google Scholar
• Ganjoo KN, Wakelee H. Review of erlotinib in the treatment of advanced non-small cell lung cancer. Biol Targets Ther 2007;1:335–46
   PubMedGoogle Scholar
• Dhillon S, Wagstaff AJ. Lapatinib. Drugs 2007;67:2101–8
   PubMed Web of Science ®Google Scholar
• Harris PA. Cancer drug design and discovery. 2nd ed. San Diego (CA): Academic Press; 2014:529–63
   Google Scholar
• Brose MS, Volpe P, Feldman M, et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 2002;62:6997–7000
   PubMed Web of Science ®Google Scholar
• Luo C, Xie P, Marmorstein RJ. Identification of BRAF inhibitors through in silico screening. Med Chem 2008;51:6121–7
   Web of Science ®Google Scholar
• Kim MH, Kim M, Yu H, et al. Structure based design and syntheses of amino-1H-pyrazole amide derivatives as selective Raf kinase inhibitors in melanoma cells. Bioorg Med Chem 2011;19:1915–23
   PubMed Web of Science ®Google Scholar
• Choi W-K, El-Gamal MI, Choi HS, et al. New diarylureas and diarylamides containing 1,3,4-triarylpyrazole scaffold: synthesis, antiproliferative evaluation against melanoma cell lines, ERK kinase inhibition, and molecular docking studies. Eur J Med Chem 2011;46:5754–62
   PubMed Web of Science ®Google Scholar
• Yurttaş L, Özkay Y, Akalın-Çiftçi G, et al. Synthesis and anticancer activity evaluation of N-[4-(2-methylthiazol-4-yl)phenyl]acetamide derivatives containing (benz)azole moiety. J Enzyme Inhib Med Chem 2014;29:175–84
   PubMed Web of Science ®Google Scholar
• Manfredini S, Bazzanini R, Baraldi PG, et al. Pyrazole-related nucleosides. 4. Synthesis and antitumor activity of some 1-tetrahydropyranyl-4-substituted pyrazoles. Anti-Cancer Drug Des 1996;11:193–204
   PubMedGoogle Scholar
• Park H-A, Lee K, Park S-J, et al. Identification of antitumor activity of pyrazole oxime ethers. Bioorg Med Chem Lett 2005;15:3307–12
   PubMed Web of Science ®Google Scholar
• Liu XH, Ruan BF, Liu JX, et al. Design and synthesis of N-phenylacetyl (sulfonyl) 4,5-dihydropyrazole derivatives as potential antitumor agents. Bioorg Med Chem Lett 2011;21:2916–20
   PubMed Web of Science ®Google Scholar
• Lv PC, Li HQ, Sun J, et al. Synthesis and biological evaluation of pyrazole derivatives containing thiourea skeleton as anticancer agents. Bioorg Med Chem 2010;18:4606–14
   PubMed Web of Science ®Google Scholar
• Lv PC, Li DD, Li QS, et al. Synthesis, molecular docking and evaluation of thiazolyl-pyrazoline derivatives as EGFR TK inhibitors and potential anticancer agents. Bioorg Med Chem Lett 2011;21:5374–7
   PubMed Web of Science ®Google Scholar
• Go ML, Wu X, Liu XL. Chalcones: an update on cytotoxic and chemoprotective properties. Curr Med Chem 2005;12:481–99
   PubMed Web of Science ®Google Scholar
• Rollas S, Küçükgüzel SG. Biological activities of hydrazone derivatives. Molecules 2007;12:1910–39
   PubMed Web of Science ®Google Scholar
• Al-Suwaidan IA, Alanazi AM, El-Azab AS, et al. Molecular design, synthesis and biological evaluation of cyclic imides bearing benzenesulfonamide fragment as potential COX-2 inhibitors. Part 2. Bioorg Med Chem Lett 2013;23:2601–5
   PubMed Web of Science ®Google Scholar
• El-Sayed MA-A, Abdel-Aziz NI, Abdel-Aziz AA-M, et al. Design, synthesis, and biological evaluation of substituted hydrazone and pyrazole derivatives as selective COX-2 inhibitors: molecular docking study. Bioorg Med Chem 2011;19:3416–24
   PubMed Web of Science ®Google Scholar
• El-Sayed MA-A, Abdel-Aziz NI, Abdel-Aziz AA-M, et al. Synthesis, biological evaluation and molecular modeling study of pyrazole and pyrazoline derivatives as selective COX-2 inhibitors and anti-inflammatory agents. Part 2. Bioorg Med Chem 2012;20:3306–16
   PubMed Web of Science ®Google Scholar
• Goda FE, Abdel-Aziz AA-M, Ghoneim HA. Synthesis and biological evaluation of novel 6-nitro-5-substituted aminoquinolines as local anesthetic and anti-arrhythmic agents: molecular modeling study. Bioorg Med Chem 2005;13:3175–83
   PubMed Web of Science ®Google Scholar
• Grever MR, Schepartz SA, Chabner BA. The National Cancer Institute: cancer drug discovery and development program. Semin Oncol 1992;19:622–38
   PubMed Web of Science ®Google Scholar
• Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 2006;6:813–23
   PubMed Web of Science ®Google Scholar
• MOE 2008.10 of Chemical Computing Group. Inc. http://www.chemcomp.com
   Google Scholar
• Stamos J, Sliwkowski MX, Eigenbrot C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem 2002;277:46265–72
   Google Scholar
• Bollag G, Hirth P, Tsai J, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010;467:596–9
   Google Scholar
• Halgren TA. Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94. J Comput Chem 1996;17:490–519
   Web of Science ®Google Scholar
• Dewar MJS, Zoebisch EG, Healey EF, et al. Development and use of quantum mechanical molecular models. 76. AM1: a new general purpose quantum mechanical molecular model. J Am Chem Soc 1985;107:3902–9
   Web of Science ®Google Scholar